Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1077-1084

  Hihara, Jun ^a   Yamaguchi, Yoshiyuki ^a   Minami, Kazuhito ^a   Noma, Kosuke ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

IL 10; Locoregional immunotherapy; OL 432; T helper 1; T helper 2

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MONOCLONAL ANTIBODY; PICIBANIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES FLUID; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EFFUSION; HELPER CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PERITONEAL EXUDATE CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASCITES; CYTOKINES; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-10; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; PICIBANIL; RNA, MESSENGER;

EID: 0032995041     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S and Shiraishi A: TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol 155: 4926-4932, 1995.
2. Mosmann TR and Moore KW: The role of IL-10 crossregulation of Th1 and Th2 responses. Immunol Today 12: A49-A53, 1994.
3. Seder RA and Paul WE: Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 12: 635-673, 1994.
4. Daftarian PM, Kumar A, Kryworuchko M and Diaz-Mitoma F: TL-10 production is enhanced in human T cells by IL-12 and IL-6 and in Monocytes by tumor necrosis factor-α. J Immunol 167: 12-20, 1996.
5. de Waal Malefyt R, Abrams J, Bennett B, Figdor C and de Vries JE: Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174: 1209-1220, 1991.
6. Howard M and O' Garra A: Biological properties of interleukin-10. Immunol Today 13: 198-200,1992.
7. Gastl AG, Abrams JS, Nanus DM, Obsterkamp R, Silver J, Liu F, Chen M, Albino AP and Bander NH: Interleukin-10 production by human carcinoma cell line and its relationship to interleukin-6 expression. Int J Cancer 55: 96-101, 1993.
8. Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS and Martinez-Meza O: Presence of interleiukin-10 (IL-10) in the ascites of patients with ovarian and other intraabdominal cancers. Cytokine 4: 385-390, 1992.
9. Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B and Kiessling R: Selective expression of interleukin-10 interferon γ and granulocyte-macrophage colony stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci USA 89: 7708-7712,1992.
10. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelin R, Yssel H and de Vries JE: Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174: 915-924, 1991.
11. Del Prete G, de Carli M, Almerigogna F, Giudizi MG, Biagiotti R and Romagnani S: Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150: 353-360, 1993.
12. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW and O' Garra A: IL-10 acts on the antigen-presenting cells to inhibit cytokine production by Th1 cells. J Immunol 146: 3444-3451, 1991.
13. Berg DJ, Leach MW, Kurn R, Rajewsky K, Müller W, Davidson NJ and Rennick D: Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J Exp Med 182: 99-108, 1995.
14. Gérard C, Bruyns C, Marchant A, Abramowicz D, Vandenbeele P, Delvaux A, Fiers W, Goldman M and Velu T: Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177: 547-550, 1993.
15. Li L, Elliott JF and Mosmann TR: IL-10 inhibits cytokine production vascular leakage and swelling during T helper 1 cell-induced delayed-type 17 hypersensitivity. J Immunol 153: 3967-3978, 1994.
16. Osward IP, Wynn TA, Sher A and James SL: Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon γ-induced activation. Proc Natl Acad Sci USA 89: 8676-8680,1992.
17. Ding L, Linsley PS, Huang LY, Germain RN and Shevach EM: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 161: 1224-1234,1993.
18. Enk AH, Saloga J, Becker D, Mohamadazdeh M and Knop J: Induction of hapten specific tolerance by interleukin-10 in vivo. J Exp Med 179: 1397, 1994.
19. Maeda H and Shiraishi A: TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 166: 73-78, 1996.
20. Romagnani S and Maggi M: Th1 versus Th2 responses in AIDS. Curr Opni Immunol 6: 616-622, 1994.
21. Furue M: Atopic dermatitis-immunological abnormality and its background. J Dermatol Sci 7: 159-168, 1994.
22. Surcel HM, Troye-Blomberg M, Paulie S, Andersson G, Moreno C, Pasvol G and Ivanyi J: Th1/Th2 profiles in tuberculiosis based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 81: 171-176, 1994.
23. Takagi E, Kawatsu H, Shimokata K, Nishiyama Y, Kojima K and Yoshida S: Establishment and characterization of resistant cells to etoposide (VP-16) from a mouse breast-cancer cell line FM3A. Jap J Cancer Res (Gann) 79: 938-944, 1988.
24. Okamoto H, Shoin S, Koshimura S and Shimizu R: Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 11: 323-326,1967.
25. Toge T, Yamada H, Aratani K, Kameda A, Kuroi K, Hisamatsu K and Hattori T: Effects of intraperitoneal administration of OK-432 for patients with advanced cancer. Jpn J Surg 16: 260-265, 1985.
26. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, Rong H, Chen J, Wang XY, Catino JJ and King I: Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184: 579-584, 1996.
27. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601, 1988.
28. Chomczynski P and Sacchi N: Single-step RNA isolation from cultured cell or tissues: Current protocols in molecular biology. John Wiley and Sons Inc, New York, 1995, pp 424-428.
29. Rugo HS, O'hanley P, Bishop AG, Pearce MK, Abrams JS, Howard M and O'garra A: Local cytokine production in a murine model of Escherichia coli pyelonephritis. J Clin Invest 89: 1032-1039, 1992.
30. Bost KL, Bieligk SC and Jaffe BM: Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies. Tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. J Immunol 154: 718-729, 1995.
31. Gorelik L, Prokhorova A and Mokyr MB: Low-dose melpharan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. CancerImmunol Immunother 39: 117-126, 1994.
32. Weiskirch LM, Bar-Dagen Y and Mokyr MB: Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalantherapy. Cancer Immunol Immunother 38: 216-224, 1993.
33. Miyahara E, Yamaguchi Y, Hihara J, Noma K and Toge T: Profile of T-cell receptor VB gene usage of cytotoxic T cells induced by intrapleural administration of a streptococcal preparation OK432 in malignant effusions. J Exp Ther Oncol 1: 242-250, 1996.
34. Yamaguchi Y, Sato Y, Miyahara E, Noma K, Funakoshi M, Takashima I, Sawamura A and Toge T: Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res 15: 2201-2206, 1995.
35. Arai T, Hiromatsu K, Nishimura H, Kimura Y, Kobayashi N, Ishida H, Nimura Y, Yoshikai Y: Effects of in vivo administration of anti-IL-10 monoclonal antibody on the host defence mechanism against murine Salmonella infection. Immunology 85: 381-388, 1995.
36. Marchant A, Bruyns C, Vandenabeele P, Ducarme M, Gérard C, Delvaux A, De Groote D, Abramowicz D, Velu T and Goldman M: Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 24 1167-1171, 1994.
37. Qin Z, Noffz G, Mohaupt M and Blankenstein T: Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 159: 770-776, 1997.
38. Gerard CM, Bruyns C, Delvaux A, Baudson N, Dargent JL, Goldman M and Velu T: Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther 7: 23-31, 1996.
39. Glovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, Consalvo M, Cavallo F, Pierro F, Giovanni C, Musso T and Forni G: Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 165: 3112-3123, 1995.
40. Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD and Lotze MT: Viral interleukin-10 (IL-10) the human herpes virus 4 cellular IL-10 homologue induces local anergy to allogeneic and syngeneic tumors. J Exp Med 182: 477-486, 1995.
41. Yamaguchi Y, Hihara J, Miyahara E, Noma K and Toge T: Up-regulation of Th1 population by locoregional administration of OK-432 in treating malignant effusions. Prc 6th Int'l Cong Anti-Cancer Treat 137, 1996.
42. Hishii M, Nitta T, Ishida H, Ebato M, Kurosu A, Yagita H, Sato K and Okumura K: Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37: 1160-1167, 1995.
43. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T and Bendig MM: Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53: 851-856, 1993.
44. Peng B, Mehta NH, Fernandes H, Chou CC and Raveche E: Growth inhibition of malignant CD5+B (B-1) cells by antisense IL-10 oligonucleotide. Leuk Res 19: 159-167, 1995.